Literature DB >> 2154996

Abnormal T suppressor cell function in juvenile rheumatoid arthritis.

E D Silverman1, C Somma, M M Khan, K L Melmon, E G Engleman.   

Abstract

The purpose of this study was to analyze T suppressor cell function in juvenile rheumatoid arthritis (JRA). JRA is a chronic inflammatory childhood disease of unknown etiology that is characterized by arthritis and immunoregulatory abnormalities. T suppressor cell precursors (CD8+, CD28-) were purified from the peripheral blood of 24 JRA patients, using a combination of monoclonal antibodies. These cells were treated with histamine or concanavalin A, agents that are known to induce suppressor activity. They were also tested for their ability to inhibit the proliferative response of autologous T cells to phytohemagglutinin. In some experiments, the accumulation of intracellular cAMP following histamine treatment was also measured. Twelve of 13 patients with clinically active JRA showed abnormal histamine-inducible T suppressor cell function, characterized by the failure of CD8+, CD28- T cells to mediate any detectable suppression. The failure of these cells to accumulate intracellular cAMP after histamine treatment was observed in 5 of 5 patients tested who had active disease. In contrast, 11 of 11 patients with clinically inactive JRA, 5 of 5 patients with cystic fibrosis, and 9 of 9 pediatric control subjects had normal histamine- and concanavalin A-inducible T suppressor cell function, and a normal cAMP response to histamine. These results suggest that patients with clinically active JRA have a reversible defect in T suppressor cell function that is associated with a failure of T suppressor cell precursors to accumulate intracellular cAMP following their exposure to selected immune stimuli.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154996     DOI: 10.1002/art.1780330208

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

Review 1.  Immunopathogenesis of juvenile rheumatoid arthritis: role of T cells and MHC.

Authors:  L I Sakkas; C D Platsoucas
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

2.  Synovial fluid cells in juvenile arthritis: evidence of selective T cell migration to inflamed tissue.

Authors:  E D Silverman; B Isacovics; D Petsche; R M Laxer
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

Review 3.  Treatment options for juvenile-onset systemic lupus erythematosus.

Authors:  Luis Carreño; Francisco Javier López-Longo; Carlos Manuel González; Indalecio Monteagudo
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

4.  Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients.

Authors:  B Crucian; P Dunne; H Friedman; R Ragsdale; S Pross; R Widen
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

5.  Quantitative alterations of CD8+ T cells in juvenile idiopathic arthritis patients in remission.

Authors:  Martina Prelog; Nora Schwarzenbrunner; Elisabeth Tengg; Michaela Sailer-Höck; Hannelore Kern; Lothar Bernd Zimmerhackl; Juergen Brunner
Journal:  Clin Rheumatol       Date:  2008-12-18       Impact factor: 2.980

6.  Lymphokines and soluble interleukin-2 receptors in juvenile chronic arthritis. Clinical and laboratory correlations.

Authors:  K Müller; F K Pedersen; A Wiik; K Bendtzen
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

7.  Successful treatment in a child with enthesitis-related arthritis involving the sternoclavicular joint: a case report.

Authors:  Po-Yu Huang; Ling-Sai Chang; Mindy Ming-Huey Guo; Ho-Chang Kuo
Journal:  BMC Pediatr       Date:  2019-10-23       Impact factor: 2.125

8.  Neutrophils Lose the Capacity to Suppress T Cell Proliferation Upon Migration Towards Inflamed Joints in Juvenile Idiopathic Arthritis.

Authors:  Sabine Arve-Butler; Anki Mossberg; Tobias Schmidt; Charlotte Welinder; Hong Yan; Elisabet Berthold; Petra Król; Robin Kahn
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.